Surface Oncology, Inc. (SURF): Price and Financial Metrics

Surface Oncology, Inc. (SURF): $1.67

0.03 (+1.83%)

POWR Rating

Component Grades














  • SURF scores best on the Growth dimension, with a Growth rank ahead of 59.72% of US stocks.
  • The strongest trend for SURF is in Quality, which has been heading down over the past 179 days.
  • SURF ranks lowest in Momentum; there it ranks in the 4th percentile.

SURF Stock Summary

  • With a one year PEG ratio of 0.8, Surface Oncology Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.18% of US stocks.
  • With a price/sales ratio of 52.25, Surface Oncology Inc has a higher such ratio than 96.24% of stocks in our set.
  • Revenue growth over the past 12 months for Surface Oncology Inc comes in at -97.87%, a number that bests only 0.83% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to SURF, based on their financial statements, market capitalization, and price volatility, are FULC, CRIS, VYGR, FUSN, and CHRS.
  • SURF's SEC filings can be seen here. And to visit Surface Oncology Inc's official web site, go to

SURF Valuation Summary

  • SURF's EV/EBIT ratio is 12.1; this is 58.7% lower than that of the median Healthcare stock.
  • Over the past 41 months, SURF's price/sales ratio has gone down 24.3.
  • Over the past 41 months, SURF's price/sales ratio has gone down 24.3.

Below are key valuation metrics over time for SURF.

Stock Date P/S P/B P/E EV/EBIT
SURF 2021-08-31 3.2 1.9 16.9 12.1
SURF 2021-08-30 3.2 1.9 16.6 11.9
SURF 2021-08-27 3.2 1.9 16.7 11.9
SURF 2021-08-26 3.1 1.9 16.1 11.4
SURF 2021-08-25 3.1 1.9 16.5 11.8
SURF 2021-08-24 3.2 1.9 16.7 11.9

SURF's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SURF has a Quality Grade of B, ranking ahead of 78.21% of graded US stocks.
  • SURF's asset turnover comes in at 0.436 -- ranking 105th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows SURF's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.436 1 0.130
2021-06-30 0.459 1 0.186
2021-03-31 0.488 1 0.247
2020-12-31 0.779 1 0.702
2020-09-30 0.278 1 -0.261
2020-06-30 0.283 1 -0.255

SURF Price Target

For more insight on analysts targets of SURF, see our SURF price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.60 Average Broker Recommendation 1.25 (Strong Buy)

SURF Stock Price Chart Interactive Chart >

Price chart for SURF

SURF Price/Volume Stats

Current price $1.67 52-week high $8.38
Prev. close $1.64 52-week low $1.37
Day low $1.61 Volume 347,700
Day high $1.73 Avg. volume 731,568
50-day MA $1.90 Dividend yield N/A
200-day MA $4.21 Market Cap 91.20M

Surface Oncology, Inc. (SURF) Company Bio

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company’s lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.

SURF Latest News Stream

Event/Time News Detail
Loading, please wait...

SURF Latest Social Stream

Loading social stream, please wait...

View Full SURF Social Stream

Latest SURF News From Around the Web

Below are the latest news stories about Surface Oncology Inc that investors may wish to consider to help them evaluate SURF as an investment opportunity.

Do Institutions Own Surface Oncology, Inc. (NASDAQ:SURF) Shares?

The big shareholder groups in Surface Oncology, Inc. ( NASDAQ:SURF ) have power over the company. Institutions often...

Yahoo | February 24, 2022

Medtronic (MDT) Q3 Earnings Top Estimates

Medtronic (MDT) delivered earnings and revenue surprises of 0.74% and 1.60%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 22, 2022

Surface Oncology to Participate in Citi's 2022 Virtual Immuno-Oncology Summit

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that company management will participate in a fireside chat during Citi's 2022 Virtual Immuno-Oncology Summit. The presentation begins at 8 a.m. ET on Wednesday, February 16, 2022. The live audio and subsequent archived webcast of the fireside chat will be accessible from th

Yahoo | February 10, 2022

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

No summary available.

Seeking Alpha | January 18, 2022

Shareholders in Surface Oncology (NASDAQ:SURF) are in the red if they invested a year ago

The nature of investing is that you win some, and you lose some. Anyone who held Surface Oncology, Inc. ( NASDAQ:SURF...

Yahoo | January 10, 2022

Read More 'SURF' Stories Here

SURF Price Returns

1-mo -9.73%
3-mo -41.81%
6-mo -67.13%
1-year -76.77%
3-year -37.22%
5-year N/A
YTD -65.06%
2021 -48.27%
2020 391.49%
2019 -55.66%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4487 seconds.